The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -3,170 | 469 |
| Amortization of debt discount | 190 | 381 |
| Depreciation and amortization | 364 | 773 |
| Amortization of right-of-use asset | 37 | 72 |
| Write-off of patent cost | 176 | - |
| Write-off of inventory | 0 | 253 |
| Bad debt expense | 8 | 9 |
| Stock-based compensation | 488 | 1,391 |
| Foreign currency transaction gains | -64 | 9,192 |
| Accounts receivable | -303 | -257 |
| Inventories | 322 | 925 |
| Prepaid expenses and other current assets | 908 | -1,897 |
| Accounts payable and accrued expenses | 193 | -360 |
| Net cash used in operating activities | -2,577 | -4,975 |
| Purchases of property and equipment | 17 | 39 |
| Payments for patent costs | -72 | 140 |
| Net cash used in investing activities | 55 | -179 |
| Proceeds from exercise of common stock warrants | 0 | 1,439 |
| Proceeds from rights offering, net of fees incurred | 0 | 5,392 |
| Net cash provided by financing activities | 0 | 6,831 |
| Effect of exchange rates on cash | -146 | 285 |
| Net change in cash, cash equivalents, and restricted cash | -2,668 | 1,962 |
| Cash and cash equivalents at beginning of period | 9,764 | - |
| Cash and cash equivalents at end of period | 9,058 | - |
Cytosorbents Corp (CTSO)
Cytosorbents Corp (CTSO)